Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$46.23M$46.23M+80.9% vs Q3 2018 Net Income-$25.02M-$25.02MN/M vs Q3 2018 EPS Diluted-$0.17-$0.17N/M vs Q3 2018 Gross Profit$6,872,000+21.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived-$29,588,000N/M Free Cash Flowderived-$30,692,000N/M Margins · derivedGross margin14.9%−7.2 pt vs Q3 2018
Operating margin-53.1%+46.6 pt vs Q3 2018
Net margin-54.1%+54.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end